

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1-7. (canceled).

8. (currently amended): A human IgM monoclonal antibody which induces apoptosis of specifically recognizing HIV-infected cells upon binding to said cells, wherein and including apoptosis of the infected cells, said antibody denominated 2G9 antibody obtainable by a cell strain with an accession No. FERM-BP 8378, and said antibody comprises a heavy-chain comprising sequence a H chain-variable region encoded by a polynucleotide comprising the nucleotide sequence of the base sequence SEQ ID No. 1SEQ ID NO: 1 and a light-chain variable region encoded by a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 2L-chain variable region encoded by the base sequence SEQ ID No. 2.

9. (currently amended): A composition comprising the antibody of Claim 8 or 11 and a pharmaceutically acceptable carrier human IgM monoclonal antibody according to Claim 8 for the treatment of HIV infection, comprising the monoclonal antibody as an effective ingredient.

10. (canceled).

11. (currently amended): The antibody of Claim 8, wherein said antibody is produced by the hybridoma deposited under Accession No. A human IgM monoclonal antibody according to Claim 8 including a cell strain with an accession No. FERM BP-8378 for producing human IgM monoclonal antibody reacting with the HIV infected cells.

12. (new): A method for treating HIV or AIDS in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of the antibody of Claim 8 or 11.